Ezgi Değerli

10PUBLICATIONS
20CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 30, 2025
Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy.

Rumeysa Colak, Caner Kapar, Ezgi Degerli

|Jan 08, 2025
Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy.

Ezgi Değerli, Çağatay Arslan, Fatih Selçukbiricik

|Jan 08, 2025
Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients.

Murad Guliyev, Özkan Alan, Murat Günaltılı

|Nov 07, 2024
Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer.

Gülin Alkan Şen, Nihan Şentürk Öztaş, Ezgi Değerli

|Aug 28, 2024
Docetaxel-induced severe neuropathy, a case of breast cancer with GTSP1 polymorphism.

Ezgi Değerli

|May 18, 2024
Prognostic factors in Kaposi sarcoma, single centre experience.

Ezgi Değerli, Kerem Oruç, Nihan Şentürk Öztaş

Pageof 2

Frequent Collaborators

4 joint publications

Nihan Şentürk Öztaş

3 joint publications

Gülin Alkan Şen

2 joint publications

Nebi Serkan Demirci

2 joint publications

Caner Kapar